Citigroup Lowers Health Catalyst (NASDAQ:HCAT) Price Target to $10.00

Health Catalyst (NASDAQ:HCAT) had its price target lowered by equities researchers at Citigroup from $10.50 to $10.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Citigroup’s price objective would suggest a potential upside of 45.14% from the company’s current price.

HCAT has been the topic of several other research reports. Evercore ISI raised their price target on Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a research note on Tuesday, October 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $16.00 price objective on shares of Health Catalyst in a research report on Friday, October 4th. KeyCorp raised Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price objective on the stock in a research report on Wednesday. Stephens raised their price target on Health Catalyst from $7.00 to $9.00 and gave the stock an “equal weight” rating in a report on Thursday, November 14th. Finally, Royal Bank of Canada raised their price target on Health Catalyst from $8.00 to $9.00 and gave the stock a “sector perform” rating in a report on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, Health Catalyst presently has a consensus rating of “Moderate Buy” and an average target price of $11.45.

Health Catalyst Stock Performance

NASDAQ:HCAT opened at $6.89 on Friday. The stock’s fifty day moving average is $7.79 and its 200 day moving average is $7.53. Health Catalyst has a fifty-two week low of $5.42 and a fifty-two week high of $11.41. The firm has a market capitalization of $419.24 million, a PE ratio of -5.10 and a beta of 1.36. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The company had revenue of $76.40 million for the quarter, compared to analysts’ expectations of $76.27 million. During the same quarter in the previous year, the company posted ($0.22) EPS. The business’s quarterly revenue was up 3.5% on a year-over-year basis. On average, sell-side analysts anticipate that Health Catalyst will post -0.33 earnings per share for the current year.

Insider Transactions at Health Catalyst

In other news, insider Linda Llewelyn sold 6,442 shares of the stock in a transaction on Monday, December 16th. The stock was sold at an average price of $7.88, for a total transaction of $50,762.96. Following the completion of the transaction, the insider now directly owns 98,702 shares in the company, valued at approximately $777,771.76. This represents a 6.13 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, General Counsel Benjamin Landry sold 19,268 shares of the stock in a transaction on Friday, December 6th. The stock was sold at an average price of $8.32, for a total value of $160,309.76. Following the transaction, the general counsel now owns 72,250 shares of the company’s stock, valued at approximately $601,120. This represents a 21.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 76,051 shares of company stock valued at $612,614 over the last ninety days. Insiders own 2.50% of the company’s stock.

Hedge Funds Weigh In On Health Catalyst

Several hedge funds have recently bought and sold shares of HCAT. Franklin Resources Inc. raised its position in Health Catalyst by 5.8% in the 3rd quarter. Franklin Resources Inc. now owns 104,141 shares of the company’s stock valued at $857,000 after purchasing an additional 5,687 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Health Catalyst by 4.9% during the 3rd quarter. Geode Capital Management LLC now owns 1,443,036 shares of the company’s stock worth $11,749,000 after acquiring an additional 66,896 shares in the last quarter. Zacks Investment Management raised its position in shares of Health Catalyst by 6.7% during the 3rd quarter. Zacks Investment Management now owns 296,121 shares of the company’s stock worth $2,410,000 after acquiring an additional 18,677 shares in the last quarter. State Street Corp raised its position in shares of Health Catalyst by 2.5% during the 3rd quarter. State Street Corp now owns 1,163,754 shares of the company’s stock worth $9,473,000 after acquiring an additional 28,251 shares in the last quarter. Finally, Quadrature Capital Ltd acquired a new stake in shares of Health Catalyst during the 3rd quarter worth about $84,000. Institutional investors and hedge funds own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.